Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
Rhea-AI Summary
Metagenomi (Nasdaq: MGX) announced that Jian Irish, Ph.D., M.B.A., President and CEO, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026 at 11:10 a.m. ET.
According to Metagenomi, the presentation will be available on the company’s Investors "News & Events" page following the event.
Positive
- None.
Negative
- None.
News Market Reaction – MGX
On the day this news was published, MGX gained 6.38%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.7% during that session. Argus tracked a trough of -5.1% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $57M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MGX is down 3.95% while most close biotech peers also show negative moves (e.g., ACET, VANI, IGMS, OSTX), indicating broader biotech pressure but with scanner data not flagging a clear sector-wide momentum move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Name change & outlook | Positive | -2.2% | Corporate rebranding plus MGX-001 timelines and cash runway update. |
| Dec 01 | Collaboration data update | Positive | -8.6% | New preclinical APOC3 data for Ionis collaboration at a Nature conference. |
| Nov 17 | Conference presentation | Neutral | -2.3% | Jefferies Global Healthcare Conference presentation and webcast availability. |
| Nov 11 | Earnings & strategy | Neutral | +2.3% | Q3 2025 results, MGX-001 plans, leadership changes and cost actions. |
| Nov 11 | Preclinical data update | Positive | +2.3% | MGX-001 dose‑range data showing curative FVIII activity in primates. |
Recent positive or milestone-focused news has often coincided with flat-to-negative next-day moves, with only clinical and earnings updates showing modest positive alignment.
Over the last six months, MGX has focused on advancing its MGX-001 hemophilia A program and refining its corporate profile. On Nov 11, 2025, Q3 earnings and pipeline prioritization, plus separate MGX-001 preclinical data, coincided with a 2.33% gain. Earlier in Nov 2025, a Jefferies conference appearance saw a small decline. A December 2025 APOC3 collaboration data presentation and a January 2026 name-change and outlook announcement both met with negative price reactions. Against this backdrop, the TD Cowen conference appearance fits a pattern of ongoing investor outreach amid mixed price responses.
Market Pulse Summary
The stock moved +6.4% in the session following this news. A strong positive reaction aligns with MGX’s pattern of better reception to clinically oriented or high-visibility events, such as prior MGX-001 data and earnings updates. However, past conference and collaboration announcements sometimes coincided with muted or negative moves, underscoring event-dependence. Investors would need to weigh whether a spike above recent levels near 1.46 reflects durable conviction or shorter-term positioning, especially given the stock’s position well below its 3.95 52-week high.
Key Terms
in vivo medical
genome editing medical
AI-generated analysis. Not financial advice.
EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. ET.
The fireside chat presentation will be made available on the “News & Events” page in the Investors section of the Company’s website at https://ir.metagenomi.co/news-events/events.
About Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, integration and correction.
MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with best-in-class treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. The Company is also currently pursuing other secreted protein deficiencies leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions include, but are not limited to, any statements relating to our product development programs, including the timing of and our ability to conduct IND-enabling studies and make regulatory filings such as INDs, expectations regarding MGX-001, including the preclinical profile being potentially competitive with best-in-class treatment options and timing to submit the IND/CTA package, statements regarding the Company’s plans to prioritize its preclinical pipeline and potential for value creation and sustainable growth, statements regarding upcoming milestones including the nomination of development candidates, statements concerning the potential of therapies and product candidates, statements concerning the impact of the organizational restructuring, statements concerning our anticipated cash runway, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contacts:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
FAQ
When will Metagenomi (MGX) present at the TD Cowen Healthcare Conference?
Who from Metagenomi (MGX) is speaking at the March 2, 2026 event?
How can investors watch Metagenomi (MGX) presentation from TD Cowen on March 2, 2026?
What is the topic of Metagenomi (MGX) at the 46th Annual TD Cowen Healthcare Conference?
Is the Metagenomi (MGX) March 2, 2026 fireside chat live or recorded?
Where on the Metagenomi (MGX) website will the TD Cowen presentation be posted?
